Meet Rapid
We do AI differently
Rooted in clinical validation and fueled by curiosity, we innovate with purpose—delivering AI-powered medical imaging and care coordination solutions that transform decision-making and improve patient outcomes.
Where depth meets breadth
Our platform drives one clear path to enhanced care, no matter where a patient seeks treatment.
We do AI better because we go beyond the algorithm.
Instill confidence
Instill confidence
Through AI-driven imaging insights backed by copious amounts of clinical validation.
Drive efficiencies
Drive efficiencies
In care team collaboration to mitigate workflow friction and wasted time.
Expand access
Expand access
To specialists, even if they’re miles away, for more equitable care.
Our history
Changing minds and guidelines
We never bought into the decades-long concept that stroke treatment had to be limited to a few short hours after the last-known well. We theorized that stroke damage was highly variable, contrary to accepted beliefs, and that far more people could be saved with the right technology.
We developed Rapid to be the engine of transformation in stroke treatment. And it did exactly what we thought it could. After years of landmark clinical trials validating Rapid, worldwide stroke guidelines expanded the treatment window from 6 to 24 hours.
The Rapid [R]evolution.
2008
2008
The first fully automated image processing platform for Neurology at Stanford University
2008
Dr. Greg Albers and Dr. Roland Bammer develop Rapid technology, the first fully automated image processing platform, at Stanford University with software engineer Matus Straka and funding from Sequoia Capital founder Don Valentine.
2009
2009
Rapid MRI software installed in eight US and one European center for the NIH-sponsored DEFUSE 2 study.
2012
2012
Dr. Albers and Dr. Bammer co-found the company iSchemaView (now named RapidAI®) and purchase the rights to Rapid technology from Stanford University.
2012
The DEFUSE 2 study shows that by using Rapid MRI, physicians can identify stroke patients who respond favorably to endovascular clot removal up to 12 hours after stroke onset.
2012
Rapid CTP was developed and installed in more than 70 North American and European sites for the SWIFT PRIME, EXTEND, and EXTEND-IA trials.
2013
2013
Rapid CTP and Rapid MRI receive FDA clearance, allowing the platform to be used in hospitals throughout the U.S.
2014
2014
SWIFT PRIME and EXTEND-IA trials document the highest favorable outcome rates ever obtained in a stroke trial and validate the use of Rapid CTP to select patients for thrombectomy within 6 hours of symptom onset.
2015
2015
American Heart Association guidelines endorse thrombectomy as a new standard of care for stroke patients who can be treated up to 6 hours after onset. Rapid platform installed in more than 100 stroke centers.
2016
2016
Rapid platform selected as the exclusive imaging selection method for the late-window trials, DAWN and DEFUSE 3.
2017
2017
The Rapid platform achieves CE Mark certification, paving the way for use in the European Union.
2018
2018
Based on the DAWN and DEFUSE 3 clinical trials that used Rapid imaging to select stroke patients for late-window treatment, the American Heart and American Stroke associations revise guidelines, extending the treatment window for acute stroke patients from 6 to 24 hours.
2018
The Rapid platform is approved for use in Canada, Australia, and New Zealand. Don Listwin is named CEO. Rapid ASPECTS announced, provides automated scoring to assess early signs of brain infarction. Rapid CTA receives FDA clearance.
2019
2019
The EXTEND trial doubles the treatment window for intravenous tPA using Rapid CTP and Rapid MRI.
2019
Rapid CTA receives CE approval, becoming the first advanced imaging product indicated for localization of a detected large vessel occlusion (LVO).
Mexico, Brazil, Japan, Israel, and Vietnam join the list of 50+ countries that approve the use of the Rapid platform.
Mexico, Brazil, Japan, Israel, and Vietnam join the list of 50+ countries that approve the use of the Rapid platform.
2020
2020
Rapid ICH launches worldwide, using artificial intelligence to quickly notify physicians of possible intracranial hemorrhage.
2020
RapidAI acquires Endovantage, an innovator in comprehensive aneurysm management—expanding scope from stroke to aneurysm.
2020
RapidAI Insights launches—offering a suite of reports and analytics on Rapid scan, treatment, and outcomes data.
AI-powered Rapid ASPECTS becomes the first ever neuroimaging solution to receive FDA clearance in the CADx (Computer-Assisted Diagnostic software) category.
AI-powered Rapid ASPECTS becomes the first ever neuroimaging solution to receive FDA clearance in the CADx (Computer-Assisted Diagnostic software) category.
2020
RapidAI hits 1 million recorded scans and is used in 1,600+ hospitals worldwide.
2020
Rapid LVO receives FDA clearance for identification of suspected large vessel occlusions.
2020
RapidAI receives $25 million in Series B funding to accelerate the company’s strategic growth initiatives.
2021
2021
Becomes the leading global AI provider in 60+ countries and 2000+ sites
2021
RapidAI grows its global footprint to over 100 countries with its technology utilized in more than 1,800 hospitals.
2021
RapidAI announces a new partnership with Penumbra to develop solutions to enable faster clinical decision-making for pulmonary embolism (PE) diagnosis and procedures.
2021
RapidAI is named the exclusive advanced neuroimaging partner for the World Stroke Organization and SIECV stroke center certification program in Latin America.
2022
2022
Expands scope from stroke to Cardiovascular, Endovascular, Aneurysm & Trauma
2022
RapidAI announces new CEO and Chief Innovation & Technology Officer
2022
RapidAI hits 5 Million+ Scans
2022
RapidAI receives FDA 510(k) Clearance for Pulmonary Embolism Triage & Notification
2022
RapidAI Receives FDA 510(k) Clearance for Rapid Hyperdensity
2022
RapidAI Applauded by Frost & Sullivan for Delivering Quality Care Quickly and Securely With Its RapidAI Platform
2022
Rapid ICH Receives New FDA Clearance with Highest Sensitivity and Specificity on the Market
2023
2023
Launches first in-class Edge Cloud platform, non-contrast CT Imaging for ischemic stroke
2023
RapidAI enhances pulmonary embolism care solution with FDA 510(k) Clearance for Rapid RV/LV
2023
RapidAI receives first and only FDA 510(k) Clearance of Rapid NCCT, a non-contrast CT imaging product to accelerate acute stroke triage
2023
RapidAI hits 10 Million+ Scans
2023
RapidAI receives $75 million in Series C funding to drive platform innovation
2023
RapidSDH receives FDA Clearance for the detection of hemispheric subdural hematomas
2024
2024
The Rapid Enterprise™ Platform and Navigator Pro™ are launched, expanding key solutions to radiology
2024
Secure FDA Clearance for perfusion imaging in the angiography suite, AngioFlow™ by RapidAI.
2025
2025
Lumina 3D™ by RapidAI is launched
2025
Rapid LVO demonstrates superiority over Viz LVO
×